Welcome to our dedicated page for The Joint news (Ticker: $JYNT), a resource for investors and traders seeking the latest updates and insights on The Joint stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect The Joint's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of The Joint's position in the market.
The Joint Corp. (NASDAQ: JYNT) will participate in two upcoming investor conferences held by B. Riley and Oppenheimer. President and CEO Peter Holt, along with CFO Jake Singleton, will represent the company. Interested investors can access a webcast of the Oppenheimer presentation on the company's investor relations website.
The Joint Corp. reported its financial results for the first quarter of 2024, showing a 5% revenue growth, 9% system-wide sales increase, and 3% system-wide comp sales rise compared to Q1 2023. The company also tripled franchise license sales, opened 23 clinics, and closed four, increasing the clinic count to 954. Adjusted EBITDA was $3.5 million, net income was $947,000, and operating income improved from a loss to $1.1 million. The company aims to be the 'Champions of Chiropractic' and highlighted their progress in revenue growth and refranchising efforts.
